Literature DB >> 19553092

Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study.

I Romera1, V Perez, J M Menchón, H Delgado-Cohen, P Polavieja, I Gilaberte.   

Abstract

PURPOSE: To evaluate social and occupational functioning in patients in partial remission (PR) compared with patients in complete remission (CR) of a major depressive disorder (MDD) episode. SUBJECTS AND METHODS: This is a six-month prospective study. PR was defined as a score more than 7 and less or equal to 15 in the Hamilton Depression Rating Scale, and CR as less or equal to 7. All patients had been on acute antidepressant treatment during the previous three months and no longer met criteria for MDD. Functioning was assessed by the Social and Occupational Functioning Assessment Scale (SOFAS).
RESULTS: Mean (S.D.) patient age was 50.5 (14.5) years (N=292) and 77% were female. At baseline, partial remitters showed greater impairment in social and occupational functioning than complete remitters (62.8 [12.6] versus 80.4 [10.5], respectively; P<.0001). After six months, only 47% PR versus 77% CR reached normal functioning, and SOFAS ratings for PR were below normal range (76.2 [12.3] PR versus 84.6 [9.4] CR; P<.0001). PR reported three times more days absent from work due to sickness than CR (63 days versus 20 days; P<.001).
CONCLUSION: We conclude that PR of an MDD episode is associated with significant functional impairment that persists even after nine months of antidepressant treatment. Our results underline the importance of treating the patient until achieving full remission. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19553092     DOI: 10.1016/j.eurpsy.2009.02.007

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  24 in total

1.  Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.

Authors:  Boadie W Dunlop; Devon LoParo; Becky Kinkead; Tanja Mletzko-Crowe; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  Am J Psychiatry       Date:  2019-02-15       Impact factor: 18.112

Review 2.  Systematic review of the neural basis of social cognition in patients with mood disorders.

Authors:  Andrée M Cusi; Anthony Nazarov; Katherine Holshausen; Glenda M Macqueen; Margaret C McKinnon
Journal:  J Psychiatry Neurosci       Date:  2012-05       Impact factor: 6.186

3.  Premorbid risk factors for major depressive disorder: are they associated with early onset and recurrent course?

Authors:  Sylia Wilson; Uma Vaidyanathan; Michael B Miller; Matt McGue; William G Iacono
Journal:  Dev Psychopathol       Date:  2014-11

Review 4.  Top-Down Control of Serotonin Systems by the Prefrontal Cortex: A Path toward Restored Socioemotional Function in Depression.

Authors:  Collin Challis; Olivier Berton
Journal:  ACS Chem Neurosci       Date:  2015-03-17       Impact factor: 4.418

5.  The prevalence and risk factors for major depression and suicidal ideation in medical residents based on a large multi-center cross-sectional study using the propensity score-matched method.

Authors:  Song Bai; Qing Chang; Da Yao; Yixiao Zhang; Bin Wu; Liping Shan
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2022-08-27       Impact factor: 4.519

6.  Factors predicting the long-term illness course in a cohort of depressed inpatients.

Authors:  Christine Kuehner; Silke Huffziger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-10-30       Impact factor: 5.270

Review 7.  Atypical interoception as a common risk factor for psychopathology: A review.

Authors:  Rebecca Brewer; Jennifer Murphy; Geoffrey Bird
Journal:  Neurosci Biobehav Rev       Date:  2021-08-03       Impact factor: 8.989

8.  Standards for Socially-and Achievement-Oriented Roles in Major Depressive Disorder and Generalized Anxiety Disorder.

Authors:  Renee J Thompson; Jenna B Borenstein; Katharina Kircanski; Ian H Gotlib
Journal:  Cognit Ther Res       Date:  2020-06-15

9.  Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis.

Authors:  Irene Romera; Víctor Pérez; Antonio Ciudad; Luis Caballero; Miguel Roca; Pepa Polavieja; Inmaculada Gilaberte
Journal:  BMC Psychiatry       Date:  2013-02-11       Impact factor: 3.630

10.  Depression treatment with duloxetine and reduction of inability to work.

Authors:  Michael Happich; Edith Schneider; Stefan Wilhelm; Thomas Zimmermann; Alexander Schacht
Journal:  Depress Res Treat       Date:  2012-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.